B Cell Immunity in Lung Transplant Rejection - Effector Mechanisms and Therapeutic Implications

Front Immunol. 2022 Mar 7:13:845867. doi: 10.3389/fimmu.2022.845867. eCollection 2022.

Abstract

Allograft rejection remains the major hurdle in lung transplantation despite modern immunosuppressive treatment. As part of the alloreactive process, B cells are increasingly recognized as modulators of alloimmunity and initiators of a donor-specific humoral response. In chronically rejected lung allografts, B cells contribute to the formation of tertiary lymphoid structures and promote local alloimmune responses. However, B cells are functionally heterogeneous and some B cell subsets may promote alloimmune tolerance. In this review, we describe the current understanding of B-cell-dependent mechanisms in pulmonary allograft rejection and highlight promising future strategies that employ B cell-targeted therapies.

Keywords: B cell; allosensitization; antibody mediated allograft rejection; chronic lung allograft dysfunction (CLAD); donor-specific antibodies; lung transplantation.

Publication types

  • Review

MeSH terms

  • B-Lymphocytes
  • Graft Rejection
  • Humans
  • Lung
  • Lung Diseases*
  • Lung Transplantation* / adverse effects
  • Transplantation, Homologous